Danaher appoints two directors and Danaher stock costs EUR 198.38

Published on 10/13/2026 at 11:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher added two directors on October 9, 2026, taking its board to 13. Danaher stock costs EUR 198.38 on October 13, 2026 before results on October 21.

Key points in brief

Danaher appointed Daniel L. Comas and Robert Hershberg to its board on October 9, 2026.
The board expanded from 11 to 13 directors, with the appointments announced on October 12, 2026.
Danaher stock was trading at EUR 198.38 at Lang & Schwarz on October 13, 2026 at 11:41 a.m. CEST.
Third-quarter results are scheduled for October 21, 2026.

Schwarz-Weiß-Reportagefoto eines Forschers am Mikroskop in einem klassischen Diagnostiklabor — Danaher Corp. Diagnostik-Labor US2358511028 in dokumentarischer Schwarzweiß-Reportage mit Forscher am alten Mikroskop, Illustration mit AI erstellt.

Danaher Corp. (ISIN US2358511028) appointed Daniel L. Comas and Robert Hershberg to its board on October 9, 2026, expanding the board from 11 to 13 directors. StockTitan reported the announcement on October 12, 2026, while Danaher stock was trading at EUR 198.38 at Lang & Schwarz on October 13, 2026 at 11:41 a.m. CEST.

Board expands to 13 directors

Comas previously served Danaher in senior finance and corporate development roles, while Hershberg brings experience in biotechnology and clinical development. The appointments add governance and scientific expertise as Danaher integrates its life sciences, diagnostics and biotechnology businesses.

The announcement also stated that Alan G. Spoon will not stand for reelection at the 2027 annual meeting. Danaher said its nominating and governance committee continues to review board composition, giving the personnel change a longer-term succession dimension.

Three dated steps in the transition

On October 1, 2026, Julie Sawyer Montgomery assumed the roles of president and chief executive officer and joined the board, according to StockTitan. On October 7, Danaher announced an autonomous laboratory designed for discovery up to eight times faster, according to StockTitan. The October 9 board appointments are the latest of the three dated developments.

What do results add to the picture?

Danaher reported second-quarter 2026 revenue of USD 6.27 billion and net income of USD 870.0 million in the standardized financial data, while Yahoo Finance described revenue growth of 5.50 percent year over year to USD 6.3 billion. The same report said core revenue growth was 3.00 percent year over year and full-year core growth was expected at 3.00 percent to 4.00 percent.

The valuation debate therefore turns on whether improving bioprocessing demand can develop into faster growth. Markets Insider reported on October 7, 2026 that Barclays raised its target from USD 230.00 to USD 255.00 and kept an Overweight rating. Morgan Stanley then raised its target from USD 220.00 to USD 240.00 on October 12, 2026, according to Markets Insider.

Upcoming dates matter

Danaher scheduled its third-quarter 2026 earnings conference call for October 21, 2026 at 8:00 a.m. ET. The company also set a USD 0.40 quarterly dividend payable on October 30, 2026, according to FinanzNachrichten.

Danaher stock was trading at EUR 198.38 at Lang & Schwarz on October 13, 2026 at 11:41 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Danaher stock.